The rate of eating disorder diagnoses among UK girls 13 to 16 years old during the first 2 years of the pandemic was 42% higher than expected, according to a study yesterday in The Lancet Child & Adolescent Health. The study also found that rates of self-harm increased 38%.

The study was based on health record from 9,184,712 patients aged 10 to 24 years (52.7%  female and 47.3% male) from January 1, 2010, to March 31, 2022. Using models, the study authors predicted the expected rates of eating disorders and self-harm, had the pandemic not occurred, from March 2020 to March 2022.

The authors found that, among 13- to 16-year-old girls, the rate of eating disorder diagnoses was 42.0% higher than expected (95% confidence interval [CI], 25.7% to 61.3%), with 3,862 observed cases compared with 2,713 projected cases. In the same cohort, the rate of self-harm diagnoses was 38% higher than expected, with 9,174 observed cases and 6,631 projected cases.

Rates were also 32.0% (95% CI, 13.3% to 53.8%) higher than expected for girls aged 17 to 19 years, whereas other age-groups showed little difference between observed and expected incidence, the authors said.

Rates for boys for both eating disorders and self-harm were lower than expected, by as much as 22.8% (95% CI, 9.2% to 34.4%) for eating disorders and 11.5% (95% CI, 3.6% to 18.7%) for self-harm.

The authors conclude that their findings indicate an urgent need for intervention.

Maintaining vigilance

In a related commentary, psychiatrist Tamsin Ford, MB BS, at the University of Cambridge, wrote, "All individuals who work with children, young people, and families should be alert to both eating disorders and self-harm in their clientele, as young people frequently conceal both these difficulties."

Young people frequently conceal both these difficulties.

"Although children and young people's services might currently bear the burden of the increased incidence, these data are a warning signal for adult mental health services, as both eating disorders and self-harm frequently persist and co-occur with other mental health conditions."

The World Health Organization (WHO) today announced that it has certified Belize as free of malaria, a culmination of a more than 70-year effort to stamp out the disease.

In its announcement, the WHO said Belize went from a peak of 10,000 cases in 1994 to 0 indigenous cases in 2019. It said the country took strategic steps to dramatically reduce its malaria burden, which included strong surveillance and vector control, which in 2015 were reoriented to focus on high-risk areas. The agency also added that trained health workers have played a key role in timely diagnosis and treatment.

This is an extra-ordinary achievement for Belize.

Jarbas Barbosa, MD, PhD, MPH, director of the WHO's Pan American Health Organization (PAHO), said Belize is the fourth country in the Americas to be certified as malaria-free and is the second in Central America to achieve the status in the past 5 years.

"This is an extra-ordinary achievement for Belize, and will also serve as inspiration for the other endemic countries in the Americas," he said. To be certified as free of malaria, a country must provide strong evidence that the chain of transmission from Anopheles mosquitoes has been interrupted nationwide for 3 consecutive years.

Possible El Nino impact on mosquito-borne illness

In related news, at a WHO media briefing on a host of global health issued today, Director-General Tedros Adhanom Ghebreyesus, PhD, said Peru is battling its worst dengue outbreak, with about 150,000 suspected cases so far, about half of them lab-confirmed. Peru has declared a state of emergency, and the outbreak has put a heavy burden on the country's health system.

Tedros said the WHO is preparing for a very high probability that 2023 and 2024 will be marked by an El Nino event, which could increase the transmission of dengue and other arboviruses such as Zika and chikungunya viruses. He added that the effects of climate change are also fueling mosquito breeding and the spread of mosquito-borne viruses.

A study of soil samples collected in a remote region of China has revealed the presence of a drug-resistant pathogenic fungus, researchers reported today in mSphere.

For the study, a team of researchers from Yunnan University in China and McMaster University in Canada collected soil samples from the Three Parallel Rivers region in

Yunnan, China, a remote and sparsely populated area that's home to more than 4,000 fungal species. They were looking to investigate the population structure and resistance levels of Aspergillus fumigatus, a ubiquitous mold and common human fungal pathogen.

Previous research by the team had found that 79% of A fumigatus samples from Yunnan greenhouses were resistant to commonly used antifungal drugs, while 15% of samples from agricultural fields, lake sediments, and forests in the region were resistant. Those findings were attributed to widespread use of agricultural fungicides.

Fungicide residues may have carried

In the present study, the researchers found that 6.95% of 331 representative A fumigatus isolates collected from 19 sites along the three rivers in January 2020 were resistant to one or both of two triazole antifungals—itraconazole and voriconazole. While that's much lower than observed in the two previous studies, the authors note that the mountainous terrain in the region is unfavorable to agricultural activities, and the use of fungicides is uncommon.

They suggest that fungicide residues from agricultural fields elsewhere in Yunnan may have been carried to non-agriculture soils, where they acted as a selective force for the emergence of resistance. Or that resistant spores from agricultural areas could have been carried to the region by wind or human activities.

These drug-resistant strains are capable of propagating very quickly and taking over local and regional populations of this species.

"Seven per cent may seem like only a small number, but these drug-resistant strains are capable of propagating very quickly and taking over local and regional populations of this species," study coauthor Jianping Xu, PhD, a professor of biology at McMaster University, said in a university press release. "There is a need for increased surveillance of drug resistance in the environment across diverse geographic regions."

Xu says future research will analyze fungal spores from air samples in the region to better understand how fungal resistance spreads.

A systematic review of studies on neonatal carbapenem-resistant Klebsiella pneumoniae (CRKP) infections indicates the pathogen is emerging as a severe threat to hospitalized newborns, particularly those in low- and middle-income countries (LMICs), researchers reported yesterday in PLOS Medicine.

The review by UK and Chinese researchers included 128 studies involving 127,583 neonates in 30 countries, including 21 LMICs, and documented 2,057 CRKP isolates collected from infected or colonized infants from 2005 to 2020. The most common sample type from infected newborns was blood (37.3%), suggesting that bloodstream infection is the main type of neonatal CRKP infection.

Among the 23 studies that reported on prevalence, the pooled prevalence of CRKP infection in hospitalized newborns was 0.3% (95% confidence interval [CI], 0.2% to 0.3%), with a significantly higher prevalence observed in Asian countries (0.7%; 95% CI, 0.4% to 1.0%) than African countries (0.3%; 95% CI, 0.1% to 0.4%). Among the 21 studies that reported on outcomes, the pooled mortality was 22.9% (95% CI, 13.0% to 32.9%).

Analysis of 535 neonatal CRKP genomes identified 146 sequence types (STs) for CRKP strains and found that ST17, ST11, and ST15 were the three most common, with ST17 documented in newborns in eight countries across four continents. Most neonatal CRKP strains (75%) carried a metallo-beta-lacatamase (MBL) gene, with New Delhi metallo-beta-lactamase the most common (64.3%) carbapenemase type, which suggests that treatment options for many neonatal CRKP infections could be limited.

Substantial global burden

The study authors say the findings indicate that neonatal CRKP infections poses a significant health burden worldwide.

"Global data on neonatal admissions are not available, but when considering these early or premature neonates only, there could be at least 60,000 estimated cases of neonatal CRKP infections with at least 5,880 estimated deaths worldwide," they wrote.

There could be at least 60,000 estimated cases of neonatal CRKP infections with at least 5,880 estimated deaths worldwide.